Novo Nordisk A/S (NYSE:NVO) shares saw unusually-strong trading volume on Monday . Approximately 5,240,036 shares traded hands during trading, an increase of 159% from the previous session’s volume of 2,021,228 shares.The stock last traded at $47.51 and had previously closed at $49.87.

Several equities analysts recently weighed in on NVO shares. Goldman Sachs Group Inc. cut Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, June 28th. Bank of America Corp. cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday. Citigroup Inc. reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Four equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $61.00.

The stock has a market capitalization of $119.54 billion and a PE ratio of 22.23. The company’s 50-day moving average is $54.18 and its 200-day moving average is $54.27.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Morgan Stanley increased its position in shares of Novo Nordisk A/S by 7.1% in the fourth quarter. Morgan Stanley now owns 1,187,053 shares of the company’s stock valued at $68,945,000 after buying an additional 79,104 shares in the last quarter. WBI Investments Inc. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $27,205,000. Roosevelt Investment Group Inc. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $24,033,000. Bank of Montreal Can increased its position in shares of Novo Nordisk A/S by 16.1% in the fourth quarter. Bank of Montreal Can now owns 64,142 shares of the company’s stock valued at $3,726,000 after buying an additional 8,892 shares in the last quarter. Finally, Pittenger & Anderson Inc. increased its position in shares of Novo Nordisk A/S by 1.1% in the fourth quarter. Pittenger & Anderson Inc. now owns 49,119 shares of the company’s stock valued at $2,853,000 after buying an additional 514 shares in the last quarter.

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.